What happened with IMNM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Immunome’s most advanced drug candidate is varegacestat for progressing desmoid tumors. It has completed a pivotal clinical trial, and the company is preparing for potential commercialization. Its broader pipeline focuses on targeted oncology treatments, including drugs that use antibodies to deliver a cancer-killing substance to cells, known as antibody-drug conjugates.
Immunome has no drugs approved for sale and has not earned revenue from product sales. Its disclosed revenue came from a research collaboration with AbbVie, but that agreement ended and will provide no further revenue. The company has primarily funded its operations by selling shares.
If varegacestat receives regulatory approval, Immunome plans to sell it in the United States through its own team focused on specialized treatment centers. Future product income depends on approval, physician adoption and adequate insurance coverage and reimbursement. Immunome also relies on outside manufacturers for later-stage development supplies and expects to use them for commercial production.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Immunome’s near-term prospects hinge on varegacestat approval and commercialization against OGSIVEO from SpringWorks, owned by Merck KGaA—not Merck & Co.
Merck & Co.’s zilovertamab vedotin competes with Immunome’s IM-1021: both use antibodies to deliver drugs to ROR1-bearing cells and are being developed for B-cell lymphomas. Merck sells medicines to wholesalers and healthcare buyers, but the signal to watch for Immunome is this program’s trial results—its Phase 2 responses in diffuse large B-cell lymphoma came with substantial toxicity at both tested doses.
Perspective Therapeutics could compete with Immunome’s IM-3050 in solid tumors: both are developing treatments that deliver radiation to FAP targets, known as radioligand therapies. Watch Perspective’s clinical progress rather than product sales; its alpha therapies remained in development, and its 2025 and 2024 revenue came from grants for National Institutes of Health work, not alpha-therapy sales.
Novartis could directly compete with Immunome’s IM-3050 in solid tumors through treatments that deliver radiation to FAP targets, known as radioligand therapies. Novartis develops and sells prescription medicines worldwide; for Immunome, watch its FAP programs’ clinical progress and news about reliable radioactive-isotope supply, which Immunome flags as a possible competitor advantage.
Immunome depends on Bristol Myers Squibb’s licensed intellectual property to develop and sell varegacestat, while bearing the development and commercialization costs itself. Bristol Myers Squibb develops, sells and licenses medicines; its agreement entitles it to milestone payments and royalties ranging from high single-digit to low-teen percentages of worldwide net sales, so eventual varegacestat sales would also create payments to BMS.
Novartis AG earningsNVS
Novartis’s report may show clinical progress and isotope supply for its FAP-targeted radioligand therapies, which could compete with Immunome’s IM-3050 for the same patients.
Look for progress in Novartis’s FAP programs and signs that radioactive-isotope supply is dependable. Advancing trials with reliable supply would bring a potential rival closer to patients; delays or unreliable supply would leave that path less mature. Immunome’s IM-3050 also faces radiotracer and treatment-site constraints, and Novartis’s progress would not show those problems are solved for Immunome.
Merck & Co., Inc. earningsMRK
Merck’s report can show whether its ROR1 drug program is advancing, a signal about competition for patients with B-cell lymphoma that Merck’s program shares with Immunome’s IM-1021.
Look for trial progress and safety information on zilovertamab vedotin. If the program advances with manageable toxicity, Immunome’s IM-1021 could face a stronger future competitor; if safety concerns continue to constrain trials, that competitive path weakens, but it says nothing definitive about IM-1021’s own safety or efficacy.
Immunome, Inc. earningsThis company
Immunome’s report will show what it spent advancing its drug pipeline and preparing varegacestat’s regulatory submission, and how that spending shaped its loss.
Read research and development expense alongside operating cash use and the cash balance. Higher development spending with faster cash use would show that trials and submission preparation are advancing at greater cost; lower spending without corresponding evidence of progress would raise the question of whether development is slowing. The balance shows resources on hand, not by itself how long they will last.
